Hirokazu Taniguchi

9.5k total citations
109 papers, 1.6k citations indexed

About

Hirokazu Taniguchi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hirokazu Taniguchi has authored 109 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 26 papers in Molecular Biology. Recurrent topics in Hirokazu Taniguchi's work include Lung Cancer Research Studies (19 papers), Lung Cancer Treatments and Mutations (18 papers) and Neuroendocrine Tumor Research Advances (10 papers). Hirokazu Taniguchi is often cited by papers focused on Lung Cancer Research Studies (19 papers), Lung Cancer Treatments and Mutations (18 papers) and Neuroendocrine Tumor Research Advances (10 papers). Hirokazu Taniguchi collaborates with scholars based in Japan, United States and China. Hirokazu Taniguchi's co-authors include Hiroyuki Aburatani, Hiroshi Mukae, Yuichi Sugiyama, Yoshitane Nozaki, Shumpei Ishikawa, Daisuke Sugiyama, Hiroyuki Kusuhara, Triparna Sen, Charles M. Rudin and S Kohno and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hirokazu Taniguchi

98 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hirokazu Taniguchi Japan 23 697 596 382 225 174 109 1.6k
Alessandro Porrello United States 23 411 0.6× 1.1k 1.8× 293 0.8× 258 1.1× 226 1.3× 40 1.9k
Adriana Zingone United States 23 430 0.6× 945 1.6× 161 0.4× 311 1.4× 185 1.1× 59 1.8k
Masaru Takenaka Japan 26 430 0.6× 927 1.6× 497 1.3× 212 0.9× 107 0.6× 145 2.1k
Afşar Barlas United States 18 410 0.6× 1.2k 1.9× 178 0.5× 169 0.8× 143 0.8× 35 2.0k
Adam Sharp United Kingdom 23 363 0.5× 687 1.2× 492 1.3× 272 1.2× 83 0.5× 65 1.4k
Damien Ambrosetti France 26 489 0.7× 867 1.5× 574 1.5× 368 1.6× 132 0.8× 90 2.3k
Gloria Peiró Spain 26 644 0.9× 737 1.2× 181 0.5× 519 2.3× 214 1.2× 64 1.7k
S. John Weroha United States 21 610 0.9× 741 1.2× 174 0.5× 368 1.6× 109 0.6× 71 1.5k
Marco Trerotola Italy 24 972 1.4× 1.1k 1.8× 452 1.2× 450 2.0× 105 0.6× 50 2.1k
Raphaël Saffroy France 27 491 0.7× 559 0.9× 343 0.9× 288 1.3× 330 1.9× 79 1.8k

Countries citing papers authored by Hirokazu Taniguchi

Since Specialization
Citations

This map shows the geographic impact of Hirokazu Taniguchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hirokazu Taniguchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hirokazu Taniguchi more than expected).

Fields of papers citing papers by Hirokazu Taniguchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hirokazu Taniguchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hirokazu Taniguchi. The network helps show where Hirokazu Taniguchi may publish in the future.

Co-authorship network of co-authors of Hirokazu Taniguchi

This figure shows the co-authorship network connecting the top 25 collaborators of Hirokazu Taniguchi. A scholar is included among the top collaborators of Hirokazu Taniguchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hirokazu Taniguchi. Hirokazu Taniguchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kanda, Shintaro, Seiji Niho, Takayasu Kurata, et al.. (2025). Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation. Clinical Cancer Research. 31(12). 2317–2326. 1 indexed citations
2.
Inomata, Minehiko, Tomomi Ichikawa, Naoki Takata, et al.. (2025). Multicenter Retrospective Analysis of Pulmonary Sarcomatoid Carcinoma Clinically Diagnosed Using Small Biopsy Specimens. Cancer Diagnosis & Prognosis. 5(3). 363–369.
3.
Honda, Koichi, et al.. (2024). Autoimmune pulmonary alveolar proteinosis presenting as localized multifocal GGOs: A case report. SHILAP Revista de lepidopterología. 19(12). 6072–6075.
4.
Soda, Hiroshi, Masataka Yoshida, Shota Nakashima, et al.. (2023). Hypertrophic osteoarthropathy associated with lung cancer: Possible links among hypoxia‐inducible factor‐1α, vascular endothelial growth factor, and hypervascularization. Thoracic Cancer. 14(14). 1320–1324. 2 indexed citations
5.
Taniguchi, Hirokazu, Ichiro Sekine, Shinnosuke Takemoto, et al.. (2023). TIM ‐3 expression induces resistance to PD ‐1 inhibitor in G‐CSF ‐producing lung spindle cell carcinoma: A case report. Thoracic Cancer. 14(36). 3556–3560. 1 indexed citations
6.
Taniguchi, Hirokazu, Rebecca Caeser, Shweta S. Chavan, et al.. (2022). WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Reports. 39(7). 110814–110814. 81 indexed citations
7.
Taniguchi, Hirokazu, Tadaaki Yamada, Shinnosuke Takemoto, et al.. (2022). Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK‐rearranged lung cancer. Cancer Science. 114(1). 164–173. 8 indexed citations
8.
Ikeda, Takaya, Shinnosuke Takemoto, Hirokazu Taniguchi, et al.. (2020). Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study. Thoracic Cancer. 11(7). 1972–1978. 5 indexed citations
9.
Miyamura, Takuto, Noriho Sakamoto, Kaori Ishida, et al.. (2020). Presence of heat shock protein 47-positive fibroblasts in cancer stroma is associated with increased risk of postoperative recurrence in patients with lung cancer. Respiratory Research. 21(1). 234–234. 9 indexed citations
10.
Taniguchi, Yoshihiko, Tadaaki Yamada, Akihiro Yoshimura, et al.. (2020). 411P Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation. Annals of Oncology. 31. S1402–S1403. 1 indexed citations
11.
Wang, Rong, Tadaaki Yamada, Sachiko Arai, et al.. (2019). Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. Molecular Cancer Therapeutics. 18(5). 947–956. 20 indexed citations
12.
Fukuda, Koji, Shinji Takeuchi, Sachiko Arai, et al.. (2019). Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status. Cancer Research. 79(7). 1658–1670. 79 indexed citations
13.
Takemoto, Shinnosuke, Minoru Fukuda, Minoru Fukuda, et al.. (2019). Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study. Thoracic Cancer. 11(2). 389–393. 3 indexed citations
14.
Ikeda, Takaya, Hiroyuki Yamaguchi, Hirokazu Taniguchi, et al.. (2018). Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma. Thoracic Cancer. 9(11). 1522–1524. 9 indexed citations
15.
16.
Yamada, Tadaaki, Joseph M. Amann, Azusa Tanimoto, et al.. (2017). Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations. Molecular Cancer Therapeutics. 17(1). 17–25. 31 indexed citations
17.
Yamaguchi, Junpei, Hitoshi Katai, Takeshi Sano, et al.. (2008). Two Cases of Gastric Adenocarcinomas after the Remission of Gastric Malignant Lymphoma treated by Chemo-Radiotherapy. The Japanese Journal of Gastroenterological Surgery. 41(9). 1682–1685.
18.
Taniguchi, Hirokazu, et al.. (2004). A Case of Metastasis From Small Cell Lung Cancer to the Spinal Cord and the Optic Chiasm. Haigan. 44(3). 179–182. 1 indexed citations
19.
20.
Taniguchi, Hirokazu, Shigeki Katoh, Jun‐ichi Kadota, et al.. (2000). Interleukin 5 and granulocyte-macrophage colony-stimulating factor levels in bronchoalveolar lavage fluid in interstitial lung disease. European Respiratory Journal. 16(5). 959–964. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessandro Porrello Breakdown of academic impact, for papers by Adriana Zingone Breakdown of academic impact, for papers by Masaru Takenaka Breakdown of academic impact, for papers by Afşar Barlas Breakdown of academic impact, for papers by Adam Sharp Breakdown of academic impact, for papers by Damien Ambrosetti Breakdown of academic impact, for papers by Gloria Peiró Breakdown of academic impact, for papers by S. John Weroha Breakdown of academic impact, for papers by Marco Trerotola Breakdown of academic impact, for papers by Raphaël Saffroy
Rankless by CCL
2026